Last reviewed · How we verify
biphasic insulin aspart 70
Biphasic insulin aspart 70 works by mimicking the body's natural insulin production to regulate blood sugar levels.
Biphasic insulin aspart 70 works by mimicking the body's natural insulin production to regulate blood sugar levels. Used for Type 1 diabetes, Type 2 diabetes.
At a glance
| Generic name | biphasic insulin aspart 70 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | insulin |
| Target | insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It consists of a rapid-acting and a longer-acting component, allowing for a more stable and controlled glucose response. This helps to prevent high blood sugar levels and associated complications.
Approved indications
- Type 1 diabetes
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Weight gain
- Allergic reactions
Key clinical trials
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (PHASE4)
- Comparison of Two Biphasic Insulin Regimens (NA)
- A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biphasic insulin aspart 70 CI brief — competitive landscape report
- biphasic insulin aspart 70 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI